Alghanim Khawla K, Alshammari Shoq O, Albaqshi Hanan T
Rheumatology Unit, Department of Internal Medicine, King Fahad Military Medical Complex, Dhahran, Saudi Arabia.
Eur J Case Rep Intern Med. 2025 Jun 5;12(7):005525. doi: 10.12890/2025_005525. eCollection 2025.
The diagnosis of systemic lupus erythematosus (SLE) typically relies on characteristic autoantibodies and standardised classification criteria, and these serological markers guide both diagnosis and treatment decisions. But in rare cases, patients present with seronegative disease, creating significant diagnostic challenges that can delay appropriate intervention. Therefore, we present a case demonstrating the importance of clinical vigilance and histopathological confirmation in seronegative SLE. A 43-year-old woman with hypothyroidism developed inflammatory polyarthritis with consistently negative autoimmune serologies - rheumatoid factor, anti-cyclic citrullinated peptide antibodies, antinuclear antibodies, and anti-double-stranded deoxyribonucleic acid antibodies - despite elevated inflammatory markers. Initial treatment with hydroxychloroquine and corticosteroids elicited a significant therapeutic response. After 5 years, she developed a rapid decline in renal function with nephritic-range proteinuria. Renal biopsy revealed crescentic immune-complex glomerulonephritis with IgG, IgM, C3, and C1q deposits, confirming lupus nephritis. Aggressive therapy with intravenous methylprednisolone, plasma exchange, and cyclophosphamide, followed by maintenance therapy with mycophenolate mofetil, hydroxychloroquine, and oral corticosteroids, achieved clinical improvement and renal stabilisation. This case demonstrates that negative serologies should not preclude a diagnosis of SLE when the clinical presentation suggests systemic autoimmunity. Early renal biopsy and aggressive immunosuppression can prevent irreversible organ damage in seronegative disease. These findings support recognising seronegative SLE as a distinct disease subset and advocate for more inclusive diagnostic approaches beyond serological testing.
Diagnosing seronegative systemic lupus erythematosus (SLE) relies on both clinical evaluation and histological findings.The absence of detectable autoantibodies does not exclude SLE; thus, a renal biopsy can assist in confirming the diagnosis.Initiating immunosuppression early is crucial to prevent permanent organ damage.
系统性红斑狼疮(SLE)的诊断通常依赖于特征性自身抗体和标准化分类标准,这些血清学标志物指导诊断和治疗决策。但在罕见情况下,患者会出现血清学阴性疾病,带来重大诊断挑战,可能延误适当干预。因此,我们报告一例病例,展示血清学阴性SLE中临床警惕性和组织病理学确诊的重要性。一名患有甲状腺功能减退症的43岁女性出现炎症性多关节炎,尽管炎症标志物升高,但自身免疫血清学检查(类风湿因子、抗环瓜氨酸肽抗体、抗核抗体和抗双链脱氧核糖核酸抗体)始终为阴性。最初使用羟氯喹和皮质类固醇治疗产生了显著的治疗反应。5年后,她出现肾功能迅速下降,伴有肾病范围蛋白尿。肾活检显示新月体性免疫复合物性肾小球肾炎,有IgG、IgM、C3和C1q沉积,确诊为狼疮性肾炎。静脉注射甲泼尼龙、血浆置换和环磷酰胺进行积极治疗,随后用霉酚酸酯、羟氯喹和口服皮质类固醇进行维持治疗,实现了临床改善和肾功能稳定。该病例表明,当临床表现提示系统性自身免疫时,血清学阴性不应排除SLE诊断。早期肾活检和积极免疫抑制可预防血清学阴性疾病中的不可逆器官损伤。这些发现支持将血清学阴性SLE视为一个独特的疾病亚组,并提倡采用超越血清学检测的更具包容性的诊断方法。
诊断血清学阴性系统性红斑狼疮(SLE)依赖临床评估和组织学发现。未检测到自身抗体并不排除SLE;因此,肾活检有助于确诊。早期开始免疫抑制对于预防永久性器官损伤至关重要。